Metoprolol-spironolactone combination for coronary heart disease with concurrent heart failure: impact on cardiac function
American Journal of Translational Research · 2026 · 18 (3) · 2247-2255
DOI: 10.62347/oeua7949 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Translational Research, 2026. Verfasst von Shujun Zhao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Affiliated Hospital of Hebei University Baoding 071000, Hebei, China. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Affiliated Hospital of Hebei University Baoding 071000, Hebei, China.
Zitieren
APA
Zhao, S., Zhang, J., & Zhao, Y. (2026). Metoprolol-spironolactone combination for coronary heart disease with concurrent heart failure: impact on cardiac function. American Journal of Translational Research, 18(3), 2247-2255. https://doi.org/10.62347/oeua7949
Vancouver
Zhao S, Zhang J, Zhao Y. Metoprolol-spironolactone combination for coronary heart disease with concurrent heart failure: impact on cardiac function. American Journal of Translational Research. 2026;18(3):2247-2255. doi:10.62347/oeua7949
BibTeX
@article{Zhao2026,
author = {Zhao, Shujun and Zhang, Jiwei and Zhao, Yansha},
title = {Metoprolol-spironolactone combination for coronary heart disease with concurrent heart failure: impact on cardiac function},
journal = {American Journal of Translational Research},
year = {2026},
volume = {18},
number = {3},
pages = {2247--2255},
doi = {10.62347/oeua7949}
}
EUVIMED